Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA
Executive Summary
An upcoming NDA filing for Hemispherx' chronic fatigue syndrome agent Ampligen may offer a sensitive case for FDA as it implements Commissioner McClellan's "strategic plan" for the agency
You may also be interested in...
Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews
FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.
Ampligen Will Be Early Test Of FDA Consolidation Of Chronic Fatigue Drug Reviews
FDA’s decision to consolidate oversight for chronic fatigue syndrome treatments in the Division of Pulmonary, Allergy and Rheumatology Products will face an early test with Hemispherx Biopharma Inc.’s expected submission of an amended NDA for its investigational agent Ampligen in the third quarter.
House Committee Watching Genasense; Show Of Force During FDA Review
The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense